Posts by Sandra Ansanay-Alex
STALICLA signs exclusive in-licensing agreement with Novartis for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
The transaction with Novartis reinforces STALICLA’s position as the leading developer of precision medicines for neurodevelopmental disorders and heralds the expansion of its portfolio into wider neuropsychiatric indications. STALICLA SA, a clinical-stage, Geneva-based, biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, announces that it has entered into an exclusive…
Read MoremimiX biotherapeutics launches a funding round to accelerate clinical translation of FastSkin®
mimiX biotherapeutics launches a funding round to accelerate clinical translation of FastSkin® MIMIX BIOTHERAPEUTICS LTD, a Swiss medical technology company focused on life sciences, with a next-generation 3D bioprinting platform using proprietary Sound Induced Morphogenesis (SIM), announces that the company is accelerating the clinical translation of FastSkin®. FastSkin® is an advanced dermal substitute for acute…
Read MoreResistell AG closes its series B first tranche of CHF 8.5 Million
Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, has taken another major step to achieving its vision by closing a first tranche of its series B financing round,…
Read MoreiOnctura awarded EUR 17.5 million funding from the EIC Accelerator
Funding will support iOnctura’s clinical program for IOA-289, a first-in-class autotaxin inhibitor for the treatment of pancreatic cancer iOnctura BV, a clinical-stage biotech developing novel cancer therapies, announces that it has been granted EUR17.5 million funding from the European Investment Council’s (EIC) Accelerator Program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists…
Read MoreAn intelligent harness to facilitate the mobility of blind people
The startup Biped created a harness equipped with 3D cameras that beeps when there is a risk of hitting an obstacle. It comes as a complement to the white cane or the guide dog. A team of engineers based in Epalinges (VD) has designed, in partnership with the Jules-Gonin Ophthalmic Hospital in Lausanne, an…
Read MoreAMF Medical SA bought for CHF 200 million by Tandem Diabetes Care
Tandem Diabetes Care, a global US-Based insulin delivery and diabetes technology company, announced an agreement to acquire AMF Medical SA, the privately held Swiss developer of the Sigi™ Patch Pump based at EPFL Innovation Park in Lausanne. The full agreement could reach CHF 200 million but is subject to future technical developments and FDA approval…
Read MoreSwiss research: the pharmaceutical industry is the leading investor in 2021
In 2021, private companies spent CHF 16.8 billion in Switzerland on in-house research and development (R&D) activities. This represents an increase of +4% per year since 2019, the year of the last survey, according to a survey carried out by the Federal Statistical Office (FSO) in partnership with economiesuisse. With an amount of CHF 6.2…
Read MoreFuture of Health Grant
The Future of Health Grant programme aims to accelerate start-ups with a digital health solution. Apply before 15 January 2027. Founded in 2022 by EPFL Innovation Park and CSS, the Future of Health Grant offers startups the financial and operational support they need at every stage—from concept inception to market validation. Beyond financial backing, the…
Read MoreNanolive selected in the top 10 Innovations by The Scientist
The Scientist magazine announced its top 10 new products selected by a panel of independent judges. The Lausanne-based start-up Nanolive is Number 5. Over the past decade, Nanolive has developed imaging platforms based on technologies that reconstruct three-dimensional holo-grams of label-free samples. In September 2021, they launched their first application-specific digital assay, LIVE T Cell…
Read MoreMRM wins the Debiopharm – La Solution – Inartis Challenge
The 7th Debiopharm-La-Solution.ch-Inartis Challenge for the Quality of Life of Patient has rewarded with a prize of CHF 25’000 the MRM project. It was selected among 5 finalists who, last July, received 5000 Swiss francs each to develop a prototype. The winner was selected by a jury of healthcare and media professionals from among…
Read More